Endofaster Robot for Gastroesophageal Submucosal Tumors: A Randomized Controlled Study

Effectiveness and Safety of the Endofaster Surgical Robot System for Precise Dissection of Gastroesophageal Submucosal Tumors: A Single-Center Randomized Controlled Study

In endoscopic treatment for gastric submucosal tumors arising from the muscularis propria, does robot-assisted surgery yield a higher serosa preservation rate, shorter operative time and lower complication rates than conventional endoscopic procedures?

For endoscopic treatment of gastric submucosal tumors originating from the muscularis propria, this study aims to explore whether robot-assisted therapy can improve serosa preservation rate, shorten operative time and reduce complications compared with conventional endoscopic surgery.

Inclusion Criteria:

1. Aged 18 to 80 years old;
2. Submucosal tumors originating from the muscularis propria of gastric fundus, highly suspected as gastrointestinal stromal tumor (GIST) confirmed by endoscopic ultrasonography (EUS) and contrast-enhanced computed tomography (CT);
3. Tumor diameter ranging from 1.0 cm to 3.0 cm;
4. No active ulcer or bleeding on the lesion surface before operation;
5. American Society of Anesthesiologists (ASA) physical status class I-III;
6. Voluntarily signed written informed consent.

Exclusion Criteria:

1. Tumor adhesion to serosa with unclear interface shown on EUS;
2. High-risk GIST or distant metastasis indicated by imaging or endoscopy;
3. History of gastric surgery or radiotherapy;
4. High bleeding risk including coagulation disorders and patients unable to discontinue anticoagulant medications;
5. Pregnant or breastfeeding women;
6. Failure to cooperate with follow-up.